biote Corp.
NASDAQ:BTMDMedical - Care Facilities
+$0.01 today
- Market cap
- $54.25M
- Beta
- 1.66
- P/E (TTM)
- 4.5
- EPS (TTM)
- $0.51
Volume 0.11M
Average 0.25M
BTMD Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
biote Corp.NASDAQ: BTMD
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures declines year over year
Q1 FY2026 capital expenditures of $1.17M (cash outflow) fell 28.3% year over year, ahead of the -37.0% change in trailing-twelve-month capital expenditures. Sequentially, it rose 8.4% from the prior quarter. Over 3 fiscal years it compounded at +39.7% a year.
Context
- Capital expenditures amounted to 2.6% of revenue in FY2025, down 0.7 pp from a year earlier.
- Capital expenditures grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -28.3% holds above the trailing-twelve-month pace of -37.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (5.02M) USD
- Year-over-year change
- +22.0%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (5.02M) | +22.0% |
| FY2024 | 2024-12-31 | (6.43M) | -137.0% |
| FY2023 | 2023-12-31 | (2.71M) | -47.6% |
| FY2022 | 2022-12-31 | (1.84M) | +51.7% |
| FY2021 | 2021-12-31 | (3.81M) | — |
Capital Expenditures vs competitors
How BTMD compares with its peers on the latest reported figures
- BTMD's LTM Mar 2026 capital expenditures of $4.74M is the 2nd largest of the 11 companies compared; the peer median is $272.66K.
- Its year-over-year change of -37.0% is the 4th highest of 10, against a peer median of -41.9%.
- Capital expenditures amounts to 2.5% of revenue for BTMD, versus a peer median of 5.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $5.43M | -41.9% | -3.0% | 4.7% | |
| LTM Mar 2026 | $4.74M | -37.0% | +39.7% | 2.5% | |
| LTM Mar 2026 | $2.88M | +380.7% | -59.9% | 8.5% | |
| LTM Mar 2026 | $1.41M | +25.4% | -36.6% | 2.5% | |
| LTM Mar 2026 | $758K | +119.1% | -51.9% | — | |
| LTM Mar 2026 | $319K | -54.6% | -39.9% | 6.2% | |
| LTM Mar 2026 | $226.33K | -55.8% | -33.4% | — | |
| LTM Mar 2026 | $218K | -38.1% | -70.5% | 19.0% | |
| LTM Mar 2026 | $9K | -89.3% | -18.2% | — | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $6 | -220.0% | — | — |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding BTMD) | $272.66K | -41.9% | -38.3% | 5.4% | |
Competitors are the stored peer set for BTMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 32.62M | 1.32M | 3.32M | 46K | 27.05M |
| Depreciation & Amortization | 1.4M | 2.2M | 2.99M | 3.57M | 3.67M |
| Deferred Income Tax | 0 | (743K) | 721K | (2.9M) | 3.98M |
| Stock-Based Compensation | 0 | 82.18M | 9.06M | 8.74M | 8.92M |
| Change in Working Capital | (1.46M) | (35.81M) | (8.93M) | 9.93M | (8.25M) |
| Accounts Receivables | (752K) | (1.56M) | (505K) | (2.27M) | (958K) |
| Inventory | (5.76M) | (1.71M) | (6.1M) | 3.71M | (6.24M) |
| Accounts Payables | 1.61M | 416K | (165K) | 1.55M | 1.01M |
| Other Working Capital | 3.45M | (32.96M) | (2.16M) | 6.94M | (2.06M) |
| Other Non-Cash Items | 1.16M | (58.3M) | 19.72M | 25.85M | (165K) |
| Operating Cash Flow | 33.72M | (9.16M) | 26.88M | 45.24M | 35.19M |
| Capital Expenditures | (3.81M) | (1.84M) | (2.71M) | (6.43M) | (5.02M) |
| Acquisitions (Net) | 0 | 0 | 0 | (11.84M) | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (2.36M) | (1.51M) | (2.35M) | (526K) | (1.85M) |
| Investing Cash Flow | (3.81M) | (1.84M) | (2.71M) | (18.8M) | (6.86M) |
| Debt Repayment | (5M) | 84.38M | (6.25M) | (6.25M) | (1.25M) |
| Common Stock Issued | 0 | 442K | 144K | 282K | 368K |
| Common Stock Repurchased | 0 | (424K) | 0 | (5.6M) | (3.37M) |
| Dividends Paid | (11.4M) | (12.89M) | (8.69M) | (4.74M) | (1.73M) |
| Other Financing Activities | (3.94M) | (8.05M) | 420K | (59.77M) | (37.58M) |
| Financing Cash Flow | (20.34M) | 63.46M | (14.38M) | (76.08M) | (43.56M) |
| Effect of Forex Changes | (12K) | 0 | (19K) | (22K) | 6K |
| Net Change in Cash | 9.56M | 52.47M | 9.77M | (49.66M) | (15.22M) |
| Free Cash Flow | 29.91M | (11M) | 24.17M | 38.81M | 30.18M |
biote Corp.
NASDAQ:BTMD
Intrinsic Alpha fair value
Locked
Current Price
$1.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.